Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.

× No keyword cloud information.

16 in total

1. Importance of complement source in measuring meningococcal bactericidal titers.

Authors: G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal: Clin Diagn Lab Immunol Date: 2001-05

2. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Authors: George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman
Journal: Pediatr Infect Dis J Date: 2010-05 Impact factor: 2.129

3. Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale.

Authors: Iaralice Medeiros de Souza; Milton Neto da Silva; Renata Chagas Bastos; Denise da Silva Gomes Pereira; Elza Cristina Schott Figueira; Ellen Jessouroun; Maria de Lourdes Moura Leal; Eliana Barreto-Bergter; Ivna Alana Freitas Brasileiro da Silveira
Journal: Glycoconj J Date: 2021-09-13 Impact factor: 2.916

4. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors: Jo Anne Welsch; Dan Granoff
Journal: Infect Immun Date: 2004-10 Impact factor: 3.441

5. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors: Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal: Infect Immun Date: 2008-12-01 Impact factor: 3.441

6. Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth.

Authors: Stephen A Spector; Min Qin; Jorge Lujan-Zilbermann; Kumud K Singh; Meredith G Warshaw; Paige L Williams; Patrick Jean-Philippe; Terence Fenton; George K Siberry
Journal: Clin Vaccine Immunol Date: 2013-04-17

7. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency.

Authors: Nima Rezaei; Asghar Aghamohammadi; Seyed Davar Siadat; Mostafa Moin; Zahra Pourpak; Mehdi Nejati; Hojat Ahmadi; Samineh Kamali; Dariush Norouzian; Bahman Tabaraei; Robert C Read
Journal: Clin Vaccine Immunol Date: 2008-01-30

Review 8. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors: Dan M Granoff
Journal: Vaccine Date: 2009-05-23 Impact factor: 3.641

9. Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

Authors: Jacqueline M Miller; Narcisa Mesaros; Marie Van Der Wielen; Yaela Baine
Journal: Adv Prev Med Date: 2011-07-18

10. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Authors: Markus Knuf; Olivier Romain; Klaus Kindler; Uta Walther; Phu-My Tran; Heidemarie Pankow-Culot; Thomas Fischbach; Dorothee Kieninger-Baum; Véronique Bianco; Yaela Baine; Jacqueline Miller
Journal: Eur J Pediatr Date: 2013-01-11 Impact factor: 3.183